Lenalidomide with rituximab for previously treated follicular lymphoma: Final appraisal document

DRAFT guidance recommends lenalidomide with rituximab, within its marketing authorisation, as an option for previously treated follicular lymphoma (grade 1 to 3A) in adults, providing company provides it according to the commercial arrangement.

Source:

National Institute for Health and Care Excellence